^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RM-046
i
Other names: RM-046
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Revolution Medicines
Drug class:
KRAS Q61H inhibitor
Related drugs:
almost2years
RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target (AACR 2023)
As far as we are aware, RM-046 is the first oral and mutant-selective inhibitor of KRASQ61H(ON). It also represents an example of a non-covalent, mutant-selective tri-complex inhibitor of a KRAS oncogenic driver mutation.
Preclinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS Q61 • KRAS Q61H
|
RMC-0708 • RM-046
Share via
